止哮散透皮给药治疗支气管哮喘临床疗效观察

Clinical Observation of "Zhixiao Powder" in Treating Bronchial Asthma by Cutaneous Penetration

目的探讨止哮散透皮给药治疗支气管哮喘的临床疗效和作用机制。方法60例轻、中度支气管哮喘缓解期患者随机分为2组,治疗组30例采用止哮散透皮给药,每周2次,共敷贴6个月;对照组30例予舒氟美、酮替芬口服,分别于治疗前后检测血清IgE和T淋巴细胞亚群及肺功能。结果中药组治疗总有效率为90.0%,对照组为66.7%(P<0.05);治疗后,中药组CD4+水平降低,CD8+水平升高,CD4+/CD8+比值下降(P<0.05),对照组CD4+/CD8+治疗前后改变无显著性(P>0.05);中药组血清IgE低于对照组(P<0.05);中药组FVC、FEV1水平升高(P<0.05),对照组肺功能无变化(P>0.05)。结论止哮散透皮给药可改善哮喘患者免疫功能及肺功能,疗效显著,值得临床推广应用。

Objective To observe the clinical efficacy and mechanism of ＂Zhixiao Powder＂ on bronchial asthma. Method Sixty patients with mild and moderate asthma were randomized into two groups. Thirty patients in treatment group received ＂Zhixiao Powder＂ by cutaneous penetration, and the other thirty patients in control group were treated with oral slow-release theophylline and ketotifen. The contents of serum IgE and T lymphocyte subsets in peripheral blood and lung function were determined before and after treatment. Result The total effective rate in treatment group was 90.0%, higher than 66.7% in control group. The ratio of CD4^＋ and CD8^＋ in treatment group was decreased, but the ratio in control group was not changed; compared with control group, the levels of IgE was lower,and FVC and FEV1 in treatment group was higher. Conclusion ＂Zhixiao Powder＂ can remarkably improve the lung function and modulate the immune function and acts effectivelv on bronchial asthma.